Aging is associated with marked changes in the timing, consolidation and structure of sleep. Older people wake up frequently, get up earlier and have less slow wave sleep than young people, although the extent of these age-related changes differs considerably between individuals. Interindividual differences in homeostatic sleep regulation in young volunteers are associated with the variable-number, tandem-repeat (VNTR) polymorphism (rs57875989) in the coding region of the circadian clock gene PERIOD3 (PER3). However, predictors of these interindividual differences have yet to be identified in older people. Sleep electroencephalographic (EEG) characteristics and circadian rhythms were assessed in 26 healthy older volunteers (55-75 years) selected on the basis of homozygosity for either the long or short allele of the PER3 polymorphism. Homozygosity for the longer allele (PER3 5/5 ) associated with a phase-advance in the circadian melatonin profile and an earlier occurrence of the melatonin peak within the sleep episode. Furthermore, older PER3 5/5 participants accumulated more nocturnal wakefulness, had increased EEG frontal delta activity (0.75-1.50 Hz), and decreased EEG frontal sigma activity (11-13 Hz) during non-rapid eye movement (REM) sleep compared with PER3 4/4 participants. Our results indicate that the polymorphism in the clock gene PER3 may contribute to interindividual differences in sleep and circadian physiology in older people.
Introduction
Aging is associated with numerous changes in sleep, such as increased number and duration of awakenings, and reduced time spent in slow wave sleep (SWS), as well as earlier wake-up time (Cajochen et al., 2006; Dijk et al., 1999) . The decline in sleep consolidation, together with the advance of sleep timing, may reflect age-related changes in the homeostatic and/or circadian aspects of sleep regulation (Cajochen et al., 2006; Dijk et al., 1999) . From the sleep homeostatic perspective, older people display a shallower dissipation of sleep pressure, as indexed by reduced SWS and slow wave activity (SWA) (electroencephalographic [EEG] power density between 0.75 and 4.5 Hz, also referred to as delta activity) dynamics across the night (Dijk and Beersma, 1989; Landolt et al., 1996) . From a circadian standpoint, aging can be associated with a reduced circadian amplitude of the core body temperature (CBT) rhythm, and a phase advance of the CBT and melatonin rhythm . However, changes in circadian parameters with aging are less consistent than age-related changes of sleep parameters, and SWS in particular. Thus, some (Czeisler et al., 1992; Münch et al., 2005; Van Coevorden et al., 1991; Weitzman et al., 1982) , but not all, studies report a decline in the amplitude of CBT, melatonin, and cortisol (Monk, 2005; Niggemyer et al., 2004; Zeitzer et al., 1999) . The disparity of these findings points to rather large interindividual differences in sleep and circadian rhythmicity with age and leaves the question open as to what is driving these individual differences (Van Cauter et al., 2000) . Progress in understanding the genetic and molecular basis of sleep and circadian rhythmicity has led to the identification of genes contributing to interindividual differences in sleep architecture, timing, and duration in humans and mice (Franken and Dijk, 2009; Landolt, 2008; Rétey et al., 2005) .
The primate-specific (Jenkins et al., 2005) , variablenumber tandem-repeat (VNTR) polymorphism within the coding region of the clock gene PERIOD3 (PER3) contains a 54-nucleotide unit that is repeated 4 (PER3 4 allele) or 5 (PER3 5 allele) times in humans (Ebisawa et al., 2001) . In young people, the PER3 VNTR predicts diurnal preference such that those homozygous for the long repeat (PER3
5/5
) prefer earlier wake-up and sleep time (Archer et al., 2003; Lázár et al., in press ). Furthermore, in young people, the PER3 VNTR polymorphism also predicts interindividual differences in sleep structure and EEG power density in non-rapid eye movement (REM) sleep, REM sleep and wakefulness (Viola et al., 2007) . PER3 5/5 individuals spent more time in SWS, have higher SWA in non-REM sleep, and a steeper dissipation of SWA during sleep episode as compared with those homozygous for the shorter, 4-repeat allele (PER3
4/4
) (Viola et al., 2007) . However, in young people, we did not observe significant differences between the genotypes with respect to the phase and amplitude of circadian markers, such as the hormones cortisol and melatonin and the clock genes PER3, BMAL1, and PER2 (Archer et al., 2008; Dijk and Archer, 2010; Viola et al., 2007) .
Since the PER3 VNTR polymorphism affects sleep regulation in young individuals, we tested the hypothesis whether this polymorphism also predicts interindividual differences in sleep of older people. Specifically, we predicted that older participants homozygous for the longer repeat (PER3
5/5
) exhibit more slow wave sleep and higher EEG power density in the delta frequency range than older participants homozygous for the shorter repeat (PER3
4/4
).
Methods

Study protocol
Recruitment of volunteers was conducted through advertisements in newspapers, e-mails, radio, and posted advertisements in the Basel and Alsace areas. The screening procedure began with an interview by telephone or in person, involving a detailed explanation of the study. A total of 168 older men and women (age range: 55-75 years) were recruited, from whom DNA samples and questionnaire data were collected. All participants gave written informed consent. The study protocol, screening questionnaires, and consent forms were approved by the local ethics committee (EKBB, Basel, Switzerland) and conformed to the Declaration of Helsinki. All potential study participants were questioned about their sleep quality, life habits, and health state. They completed a consent form, the General Medical Questionnaire, the Short Form-36 (SF-36) Quality of Life Questionnaire, the Horne-Östberg Questionnaire, the Munich Chronotype Questionnaire, the Pittsburgh Sleep Questionnaire, the Epworth Sleepiness Scale, the Beck Depression Inventory, and the Insomnia Severity Index Questionnaire. Exclusion criteria were medical and sleep disorders, smoking, medication or drug consumption, shift work within the last 3 months, and transmeridian flights during 2 months before the study.
For the genotyping, all potential participants provided buccal swab samples, from which genomic DNA was extracted via the QuickExtract system (Epicentre Biotechnologies, Madison, WI, USA). Genotyping was performed with polymerase chain reaction (PCR) as previously described (Archer et al., 2003) with some modification (Vandewalle et al., 2009) .
Volunteers with good general health were included in the field study. Forty participants wore actigraphs (wrist-worn Actiwatch L, Cambridge Neurotechnology, Cambridge, UK) to quantify their rest-activity profile and completed daily sleep diaries for approximately 3 weeks prior to the laboratory study. Complete data were obtained from 37 subjects, out of which 21 were PER3 5/5 (8 men, 13 women, mean Ϯ standard error of the mean [SEM] ϭ 63.02 Ϯ 1.18, in years) and 16 were PER3 4/4 participants (8 men, 8 women, mean Ϯ SEM ϭ 63.38 Ϯ 1.28, in years). The first 2 weeks were analyzed to characterize the habitual sleepwake cycle for each study participant, who was then instructed to sleep and wake-up according to his/her habitual schedule for 1 week prior to the laboratory study. Compliance was verified by analysis of the sleep diaries and actigraphy data prior to the laboratory study. Participants who successfully completed the 3-week actigraphy underwent a medical examination, blood screening, and a polysomnography recorded adaptation night to exclude sleep disorders. Exclusion criteria were Ͼ 10 periodic leg movements per hour and an apnea-hypopnea index Ͼ 10. Thirteen PER3 4/4 individuals and 13 PER3 5/5 individuals were matched by age, body mass index, gender, and ethnicity and included in the laboratory part of the study. Table 1 describes the main demographic characteristics of these participants, together with data derived from questionnaires and the sleep-wake timings derived from sleep diaries.
Laboratory study
The laboratory part consisted of a baseline sleep episode, followed by approximately 40 hours of extended wakefulness under constant routine (CR) conditions, and a subsequent recovery sleep episode. The CR protocol (Duffy and Dijk, 2002a) was employed to assess the circadian phase and amplitude as well as homeostatic aspects of sleep regulation, which involved 40 hours of extended wakefulness under constant environmental conditions (i.e., light Ͻ 8 lux at eye level, temperature approximately 21°C, regular small isocaloric meals and water, semirecumbent position during scheduled wakefulness, and no information of clock time).
CBT was continuously recorded at 20-second intervals using an indwelling rectal probe (Interstar, Cham, Switzerland; Therm, type 5500-3, Ahlborn, Holzkirchen, Gemany). The temperature was displayed on a personal computer screen and continuously monitored by a laboratory technician. Hourly saliva samples were collected to measure melatonin and cortisol. All participants received heparin (0.2 mL Fragmin, Pfizer, New York NY, USA) at the beginning of the CR and 20 hours afterward, to avoid possible thrombosis. They were attended by technicians throughout the entire CR.
Polysomnography measures
The Vitaport ambulatory system (Vitaport-3 digital recorder, TEMEC Instruments BV, Kerkrade, the Netherlands) was used for all polysomnography recordings. Eight EEG channels (F3, F4, C3, C4, P3, P4, O1, O2) referenced against linked mastoids (A1, A2), 2 electro-oculograms, 2 submental electromyograms, and 2 electrocardiograms were recorded. All EEG signals were low pass filtered at 30 Hz (fourth order Bessel type antialiasing, total 24 decibels per octave) at a time constant of 1.0 second. After online digitization by using a 12-bit analog-to-digital converter (0.15 V/bit) and a sampling rate at 128 Hz for the EEG, the raw signals were stored on a Flash RAMCard (Viking, Rancho Santa Margarita, USA) and later downloaded to a PC hard drive. Sleep stages were visually scored per 20-second epochs (Vitaport Paperless Sleep Scoring Software, Kerkrade, the Netherlands) according to standard criteria (Rechtschaffen and Kales, 1968 ) by a single experienced polysomnography technician, blind to the genotype. Sleep stages were reported as percentages of total sleep time (TST). Sleep latency was defined as latency from lights off to the first epoch of stage 2. Slow wave sleep was defined as the sum of stages 3 and 4 and non-REM sleep as the sum of stages 2, 3, and 4.
Spectral analysis was conducted using a fast Fourier transform (FFT; 10% cosine 4-second window) which yielded a 0.25-Hz resolution. To examine EEG power density in the range of 0.75-20 Hz during non-REM and REM sleep for both genotypes, all-night EEG power density during the baseline and recovery nights was computed for frontal (F3, F4), central (C3, C4), parietal (P3, P4), and occipital (O1, O2) derivations for each 0.25-Hz frequency bin. To further explore the effects of the 40 hours of extended wakefulness between the genotypes, we computed the difference of recovery and baseline non-REM sleep EEG power density from 0.75 to 20 Hz in PER3 4/4 and PER3 5/5 individuals. Data of frontal EEG power density during recovery sleep was excluded for 1 participant due to artifacts across the entire night.
Hormonal assays
Saliva collections for melatonin and cortisol were scheduled every 60 minutes, during the 40 hours of extended wakefulness. A direct double-antibody radioimmunoassay was utilized for the melatonin assay (validated by gas chromatography mass spectroscopy with an analytical least detectable dose of 0.65 pm/mL; Bühlmann Laboratory, Schönenbuch, Switzerland) (Weber et al., 1997) . Cortisol was measured by ALPCO (American Laboratory Products Company Diagnostics, Salem, NH, USA), using a direct salivary enzyme-linked immunosorbent assay (ELISA) for quantitative determination of cortisol by enzyme immunoassay. Sensitivity was 1.0 ng/mL and intra-assay coefficient of variances was 10.3% for baseline values (b) 6.6 ng/mL.
Statistical analysis
All statistical analyses were performed with SAS version 9.1 (SAS Institute, Cary, NC, USA). To examine EEG power density in the range of 0.75-20 Hz during non-REM sleep for both genotypes, all-night EEG power density during the baseline and recovery nights was computed for frontal, central, parietal, and occipital derivations for each 0.25-Hz frequency bin. Comparisons between genotypes were made with mixed-model analyses of variance for repeated measures (PROC Mixed), with factors "genotype" (PER3 4/4 and PER3
5/5
), "night" (baseline and recovery), "time," and "derivation" (frontal ϭ F3 and F4; central ϭ C3 and C4; parietal ϭ P3 and P4; occipital ϭ O1 and O2). Contrasts were assessed with the LSMEANS statement. All p-values were based on Kenward-Roger's corrected degrees of freedom. To investigate the decay of non-REM EEG delta-power density, we first performed a detection of each quarter Hz within the delta frequency range (0.75-4.0 Hz) that had a significant "genotype" effect (0.75-1.50 Hz). This delta range was then utilized to assess the decay of delta activity (on absolute values) for the first 6 hours after sleep onset for EEG of baseline and recovery nights between the genotypes. An exponential decay function (PROC NLIN, SAS 9.1) was fitted as follows: delta ϭ deltaϱ ϩ delta0 ϫ e -r/t , whereby delta0 ϭ intercept on y axis, delta ϭ EEG delta power per hour, r ϭ slope of decay, t ϭ time of hour midpoint.
For the analysis of circadian variables such as CBT, melatonin, cortisol, and rest-activity we used a number of approaches. To estimate whether there was an overall effect of genotype, we applied a 2-way r-analysis of variance (ANOVA) with factors "genotype" and "time," the alpha adjustment for multiple comparisons was applied according to Curran-Everett (2000) . To estimate the timing and amplitude of rhythmic functions of these circadian variables, we also used a nonlinear regression procedure (PROC NLIN, SAS 9.1), whose function fitted to the data was: Value (sample t i ) ϭ Mesor ϩ Amplitude ϫ sin ((sample t i -phase)/24.2) in which the mesor, amplitude, and phase were free parameters, t i represents the clock time i at which a sample was collected, and value represents the value of the circadian marker variable. Determination of a fitted function for CBT was based on the model: temp ϭ Mesor ϩ Amplitude ϫ sin ((sample t i -phase)/24.2) for the analyses of cortisol and melatonin, data were z-scored to provide a normalized comparison of amplitudes across these variables. This approach first equates the total variance in each variable in each individual, and then determines how much of this variance can be attributed to a circadian signal. The phase of the melatonin rhythm and cortisol was defined on the basis of the timing of the fitted maximum. In addition, we estimated the phase of the melatonin rhythm, defined as the time of the midpoint between the upward and downward mean crossing. In each individual, the average concentration of melatonin was calculated and the time of the upward and downward crossing of the mean was determined with linear interpolation (Zeitzer et al., 1999) . This method of phase determination is robust against individual differences in the amplitude of the melatonin rhythm. Circadian CBT phase was defined as the fitted minimum. The phase angle, or time interval, between habitual wake-up and sleep times and circadian phase was calculated by subtracting the time of fitted melatonin maximum from habitual wake-up and sleep times for each subject (Duffy et al., 2002b) . 
Results
Demographic and sleep-wake characteristics
Circadian markers: rest-activity cycle
Rest-activity cycles quantified by actigraphy during the field study differed between the genotypes, such that the ANOVA revealed a significant interaction for the factors "genotype" and "time" (F ϭ 1.31; p ϭ 0.04) (Fig. 1) . Furthermore, the assessment of the onset of activity by fitting a rhythmic function to the data revealed a significant difference between the genotypes, such that PER3 5/5 participants had an earlier onset of activity, as compared with PER3 4/4 participants (mean Ϯ SEM: PER3 5/5 ϭ 04:42 Ϯ 00:51 and PER3 4/4 ϭ 06:54 Ϯ 00:25, in hours; t test; p ϭ 0.04).
Circadian markers: CBT, cortisol, and melatonin
Analyses of the circadian rhythms of CBT and cortisol did not yield statistically significant differences between the genotypes (Fig. 2) . By contrast, the analysis of the melatonin profile yielded a significant interaction for the factors "genotype" ϫ "time" (F ϭ 1.74; p ϭ 0.011). Furthermore, estimation of circadian phase with a nonlinear regression procedure yielded a significant phase advance of the fitted melatonin maximum in the PER3 5/5 (mean Ϯ SEM ϭ 01: 52 Ϯ 00:11, in hours) compared with the PER3 4/4 participants (mean Ϯ SEM ϭ 02:40 Ϯ 00:18 in hours). These results were corroborated by the significantly earlier melatonin midpoint in the PER3 5/5 (mean Ϯ SEM ϭ 02: 18 Ϯ 00:15 in hours) compared with the PER3 4/4 volunteers (mean Ϯ SEM ϭ 03:40 Ϯ 00:33 in hours; t test; p ϭ 0.03). Analysis of the phase relationship between average wake-up time and timing of melatonin midpoint yielded no significant differences between the genotypes. However, the interval between the average sleep time and melatonin mid- point was significantly shorter for PER3 5/5 (mean Ϯ SEM ϭ 02:54 Ϯ 00:18, in hours) than for PER3 4/4 participants (mean Ϯ SEM ϭ 03:44 Ϯ 00:12, in hours; t test; p ϭ 0.02).
Baseline and recovery sleep structure
A 2-way r-ANOVA yielded a significant interaction for factors "genotype" ϫ "night" for total sleep time (p ϭ 0.04), and a trend for a significant interaction between these factors for sleep efficiency (p ϭ 0.07) and wakefulness (p ϭ 0.06) ( Table 2 ). Main effect "night" was significant for total sleep time, sleep efficiency, non-REM stage 1, and SWS (% of total sleep time) (p Ͻ 0.05). When the analyses were restricted to the baseline night, PER3 5/5 participants had lower sleep efficiency, and more wakefulness than the PER3 4/4 participants (p Ͻ 0.05). Analysis of the time course of sleep consolidation, as indexed by accumulated wakefulness, revealed that PER3 5/5 participants had significantly more wakefulness during baseline night than PER3 4/4 (Wilcoxon 2-sample test p Ͻ 0.05), after 4 hours of sleep onset (Fig. 3, left panel) . These results were further corroborated by a 2-way r-ANOVA on the number of awakenings (per hour), which yielded a significant "genotype" effect (F ϭ 4.04; p ϭ 0.04) (Fig. 3, right panel) .
Baseline and recovery sleep EEG power density
A 3-way r-ANOVA with the factors "genotype," "derivation," and "night" yielded a significant main effect for the factor genotype in the frequency range of 0.75 to 1.50 Hz (delta range) and of 11 to 13 Hz (sigma range) (p Ͻ 0.05). The main effect of "night" was significant in the frequency range of 0.75-10.25 Hz and 15.50 -20 Hz (p Ͻ 0.05). The 2-way interaction of the factors "genotype" ϫ "derivation" was significant in the frequency range of 0.75-6.5 Hz and of 8.75-17.25 Hz (p Ͻ 0.05). The 2-way interaction "genotype" ϫ "night" and the 3-way interaction "genotype" ϫ "night" ϫ "derivation" yielded no significant differences. Fig. 4 shows that, during the baseline night, PER3 5/5 individuals had higher frontal EEG power density in 0.75-1.50 Hz (delta range) than the PER3 4/4 individuals. Conversely, during the baseline and recovery nights, PER3 5/5 individuals had lower frontal EEG power in 11-13 Hz (sigma range) than the PER3 4/4 individuals. Furthermore, only during the baseline night, PER3 5/5 individuals had higher occipital EEG power density in the frequency range of 5-6 Hz. Analysis of the effects of 40 hours of extended wakefulness (difference of recovery and baseline nights) revealed no significant differences in the response to sleep deprivation in non-REM sleep EEG power density in the frequency range from 0.75 to 20 Hz between PER3 4/4 and PER3
5/5
individuals (Fig. 5) . REM sleep EEG power density did not significantly differ between the genotypes during either the baseline or the recovery night (data not shown).
Given the differential levels of the absolute values of delta activity between the genotypes, we computed the exponential decay function (Delta ϭDeltaϱ ϩ Delta0 ϫ e -r/t ) for frontal non-REM delta activity (by hour), first on an individual basis and then by computing the average parameters for all-night duration of EEG of baseline and recovery nights. A 2-way r-ANOVA yielded a significant interaction for the factors "genotype" ϫ "time" for delta activity (F ϭ 2.89, p ϭ 0.04). Homozygosity for the longer : 11.6 Ϯ 2.7 hours [mean Ϯ SEM]; t test; p Ͻ 0.05). After challenging the sleep homeostat by 40 hours of extended wakefulness, delta activity was increased in both the genotypes. However, no significant differences between the genotypes were observed for the amount of delta activity and the rate of dissipation (Fig. 6) .
Discussion
The data show that, in older individuals, the PER3 VNTR polymorphism significantly contributes to individual differences in the rest-activity timing, circadian rhythmicity, and the spectral composition of the EEG during non-REM sleep. Homozygosity for the longer allele (PER3
5/5
) was associated with an earlier activity onset in the morning, an earlier melatonin midpoint, and a shorter interval (phaseangle) between the average sleep time and melatonin midpoint. PER3 5/5 participants had reduced sleep efficiency and more wakefulness; only during baseline sleep. PER3 5/5 participants showed increased frontal non-REM delta (0.75-1.50 Hz) and decreased frontal sigma activity (11-13 Hz) during baseline sleep, while during recovery sleep only frontal sigma activity was decreased. Furthermore, the response to the effects of extended wakefulness was similar Key: ANOVA, analysis of variance; BN, baseline night; PSG, polysomnographic; REM, rapid eye movement; RN, recovery night; SWS, slow wave sleep; TST, total sleep time. between the genotypes. Our current findings indicate that in older participants both the circadian and the homeostatic processes seem to be differentially affected by the PER3 VNTR. Thus, we replicated the previous finding in young participants (Viola et al., 2007) that the PER3 polymorphism predicts interindividual differences in sleep (i.e., non-REM delta activity) in an independent sample comprising older participants. However, we did not replicate the increase in visually scored SWS in young PER3 5/5 , probably due to the very low levels of SWS in older people. The novel aspect of our current study in older people is that the PER3 polymorphism also impacts on the timing of robust circadian markers, such as melatonin.
As expected, the sleep and wake-up times of the current sample of older people was earlier, with higher morningness scores than in the group of young subjects (Viola et al., 2007) . The 2 genotype groups were stringently matched for key demographic characteristics, such as age, body mass index (BMI), etc. Thus, it is uncertain how the higher daytime sleepiness score in PER3 4/4 participants relates to the other genotype-dependent changes in sleep and circadian variables. The advance of the melatonin profile and shorter internal phase relationship between the sleep-wake cycle and the melatonin rhythm indicate that PER3 5/5 older volunteers slept later relative to the timing of the evening increase in melatonin levels. It remains uncertain if these changes in circadian phase and internal phase relationship in older PER3 5/5 volunteers are driven by changes in the period of the circadian oscillator, or differences in light sensitivity or altered light exposure associated with sleep timing. Interestingly, we found no differences with respect to the phase-angle of melatonin and wake-up time. Older participants wake up earlier relative to the morning decline in their melatonin levels (Duffy et al., 2002b) and the nadir of the core body temperature rhythm (Duffy et al., 1998) , which suggests that older individuals may be waking up at an earlier circadian phase. Furthermore, changes in the internal phase angle have also been observed in young morning types (Duffy and Czeisler, 2002c) and the PER3 5/5 polymorphism is associated with morningness in young adults (Archer et al., 2003; Lázár et al., in press ). Thus, aging and diurnal preference have been associated with changes in the phase angle between sleep and the melatonin rhythm (Dijk and Lockley, 2002) , and our results imply that these changes are modulated by the PER3 VNTR polymorphism.
Aging is associated with a reduction of sleep consolidation, with more awakenings in particular from non-REM sleep, which suggests an attenuation of the protective non-REM role for sleep with aging (Dijk et al., 2001 ). In our study, sleep consolidation was lower in PER3 5/5 participants than in PER3 4/4 in particular during the second half of the baseline sleep, when homeostatic sleep pressure is low. From a circadian perspective, the reduced sleep consolidation in PER3 5/5 older participants may reflect a diminished strength of the circadian drive for sleep.
Sigma activity, which correlates well with sleep spindle activity (Dijk and Czeisler, 1995) , was reduced in PER3 5/5 individuals. Sleep spindles comprise the interplay of reticular thalamic, thalamocortical, and cortical pyramidal cells (Steriade et al., 1993) , and are under circadian control (Dijk and Czeisler, 1995; Wei et al., 1999) , such that the circadian pacemaker actively promotes spindles during the night, presumably to promote sleep consolidation (Dijk and Czeisler, 1995) . Sleep spindles have been described as inhibitory events that can predict sleep stability (Dang-Vu et al., 2010) , and both its frequency and its circadian modulation can decline with age (Dijk and Czeisler, 1995; Wei et al., 1999) . Furthermore, the circadian modulation of sleep spindle characteristics varies with brain location, such that the major difference is between frontal and parietal spindle frequency activity (Cajochen and Dijk, 2003) . Frontal spindles were found to have a lower frequency (approximately 12 Hz) than parietal spindles (approximately 14 Hz). The observation that our genotype dependent changes in spindle activity were observed for a lower frequency range (11-13 Hz), and that these differences were most apparent in frontal brain areas, may indicate that the age-related decrease in sigma activity is modulated by the PER3 VNTR, presumably through changes in the circadian promotion of spindle activity.
Homozygosity for the longer allele (PER3
) affected baseline EEG power density, with increased non-REM fron- tal delta activity. At the beginning of sleep, delta activity, particularly in frontal derivations, acts as a functional index of increased homeostatic sleep pressure (Borbély et al., 1981; Cajochen et al., 2001 ). Thus, our findings indicate that, as for young individuals, the dynamics of the sleep homeostatic process also differ between older PER3 5/5 and PER3 4/4 individuals. Furthermore, in the absence of sleep deprivation, PER3 5/5 individuals initiate sleep at a higher homeostatic level and display a faster dissipation of this sleep pressure. The lower dissipation rate in delta activity observed in our older participants is in accordance with previous observations and is largely independent of topography (Münch et al., 2004) . Interestingly, very large interindividual differences in the dissipation slope were observed for the PER3 4/4 but not for PER3 5/5 participants, particularly after sleep deprivation. Whether or not this is related to other differences between the genotypes remains unknown.
The topographical distribution of delta activity is such that, during both sleep and wakefulness, the homeostatic increase in low-EEG components is most prominent in frontal brain areas (Cajochen et al., 1999; Finelli et al., 2000) , indicating higher susceptibility to the effects of sleep deprivation. Our results on frontal delta activity indicate that PER3 5/5 may experience higher sleep pressure, as compared with PER3 4/4 participants, and that the frontal cortex is the most susceptible to the effects of this higher sleep pressure. With respect to the occipital derivation, to our knowledge there are no previous studies that have shown such frequency-unspecific changes in this derivation with advanced age. Thus, the reason as to why we observed higher EEG power density in PER3 5/5 participants (across all frequency ranges) remains elusive. Aging affects both the homeostatic and the circadian aspects of sleep, and the present data seem to indicate that these age-related changes are more prominent in PER3 5/5 older volunteers. Our study sample did not include young PER3 5/5 and PER3 4/4 volunteers, thus we could not conduct a direct age-related comparison for the homeostatic and circadian changes. Furthermore, even a direct comparison would only constitute a cross-sectional comparison and not establish whether the PER3 VNTR interacts with the aging process per se, as this would require a longitudinal study. The present data show that key aspects of age-related changes in sleep and circadian rhythmicity, such as earlier melatonin phase, shorter phase-angle, reduced sigma activity, and sleep consolidation, are more pronounced in PER3 5/5 older volunteers. Thus, we speculate that PER3 5/5 individuals show more distinct age-related changes commonly seen in sleep structure and circadian phase. These data have implications for our understanding of the interindividual differences in agerelated changes in sleep and circadian rhythmicity.
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